Latest stories on HRTX
Heron Therapeutics GAAP EPS of -$0.03 misses by $0.02, revenue of $37.67M misses by $4.53M
Seeking Alpha28 · bearishearnings
HERON THERAPEUTICS, INC. /DE/ (HRTX) files 8-K
SEC 8-K50 · neutralgeneral
Heron Therapeutics Announces Second Quarter 2026 Financial Results
Business Insider63 · neutralearnings
Heron Therapeutics to Report Second Quarter 2026 Financial Results on Monday, August 10, 2026
Business Insider50 · neutralgeneral
Is Heron Therapeutics, Inc. (HRTX) Stock a Recovery Opportunity After Cinvanti Patent Court Ruling?
Yahoo Finance56 · neutralanalyst
Heron Therapeutics Faces Nasdaq Minimum Bid Price Deficiency
TipRanks38 · neutralgeneral
HERON THERAPEUTICS, INC. /DE/ (HRTX) files 8-K
SEC 8-K34 · bearishgeneral
HERON THERAPEUTICS, INC. /DE/ (HRTX) files 8-K
SEC 8-K50 · neutralgeneral
Heron Therapeutics In A Tough Spot After Cinvanti Court Loss (Rating Downgrade)
Seeking Alpha28 · bearishgeneral
Heron Therapeutics Appeals Ruling Invalidating CINVANTI Patents
TipRanks48 · neutralgeneral
U.S. District Court Issues Decision Regarding CINVANTI® Patents | HRTX Stock News
StockTitan50 · neutralgeneral
Why Heron Therapeutics, Inc. (HRTX) Price Target Was Reduced to $4 at H.C. Wainwright?
Yahoo Finance38 · neutralanalyst
Heron Therapeutics, Inc. 2026 Q1 - Results - Earnings Call Presentation
Seeking Alpha50 · neutralearnings
Heron Therapeutics, Inc. Q1 2026 Earnings Call Summary
Yahoo Top50 · neutralearnings
Heron Therapeutics Q1 Earnings Call Highlights
Yahoo Top56 · neutralearnings
Acute Care Revenue Growth Helps Heron (HRTX) Reaffirm 2026 Guidance Despite Q1 Sales Decline
Yahoo Finance56 · neutralearnings